EEF1A1 and metabolic dysfunction-associated steatotic liver disease: Whether increased hepatocyte eEF1A-1 protein and its subcellular redistribution are markers of NAFLD progression, and whether inhibition of eEF1A-1 activity has therapeutic potential, remain as possibilities for further investigation.